` ONCT (Oncternal Therapeutics Inc) vs S&P 500 Comparison - Alpha Spread

ONCT
vs
S&P 500

Over the past 12 months, ONCT has underperformed S&P 500, delivering a return of -88% compared to the S&P 500's +15% growth.

Stocks Performance
ONCT vs S&P 500

Loading
ONCT
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
ONCT vs S&P 500

Loading
ONCT
S&P 500
Difference
www.alphaspread.com

Performance By Year
ONCT vs S&P 500

Loading
ONCT
S&P 500
Add Stock

Competitors Performance
Oncternal Therapeutics Inc vs Peers

S&P 500
ONCT
ABBV
AMGN
GILD
VRTX
Add Stock

Oncternal Therapeutics Inc
Glance View

Market Cap
1.6m USD
Industry
Biotechnology

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The company is headquartered in San Diego, California and currently employs 26 full-time employees. The company went IPO on 2004-02-03. The firm is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. Its product candidates include Zilovertamab, ONCT-808, ONCT-534 and ONCT-216. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1), a growth factor receptor that is expressed on many tumors and that activates pathways to increased tumor proliferation, invasiveness and drug resistance, and bind to a specific functionally important epitope of ROR1. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases.

ONCT Intrinsic Value
4.5151 USD
Undervaluation 88%
Intrinsic Value
Price
Back to Top